ACBD3

Across TCGA pan-cancer cohorts, ACBD3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ACBD3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ACBD3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ACBD3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LUAD, COAD, and LSCC are the cancer types where ACBD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACBD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	+0.755	<.001	9	view →
COAD	Female	III,IV	+0.286	<.001	9	view →
LSCC	Female	All	+0.409	<.001	8	view →
CCRCC	All	II,III,IV	+0.135	<.001	8	view →
PDAC	Female	II,III,IV	−0.388	<.001	4	view →
OV	All	All	+0.373	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ACBD3–LUAD

Open the LUAD breakdown →